Relative bioavailability of different buprenorphine formulations under chronic dosing conditions

Drug and Alcohol Dependence

Volumn 74, Issue 1, 2004, Pages 37-43

  Strain, Eric C ^a   Moody, David E ^b   Stoller, Kenneth B ^a   Walsh, Sharon L ^a   Bigelow, George E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Buprenorphine; Formulation; Pharmacokinetics; Pharmacotherapy; Treatment

Indexed keywords

BUPRENORPHINE; NALOXONE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; FEMALE; HUMAN; MALE; OPIATE ADDICTION; OUTPATIENT; PRIORITY JOURNAL; TABLET;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BUPRENORPHINE; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; MALE; OPIOID-RELATED DISORDERS;

EID: 1842608970     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2003.11.008     Document Type: Article

References (25)

1. Amass L., Bickel W.K., Crean J.P., Blake J., Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacol. Berlin. 136:1998;217-225.
2. Bickel W.K., Amass L., Crean J.P., Badger G.J. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacol. Berlin. 146:1999;111-118.
3. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1995. Structured Clinical Interview for DSM-IV Axis I Disorders. Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
4. Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., Pezawas L., Aschauer H.N., Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 94:1999;1337-1347.
5. Harris D.S., Jones R.T., Welm S., Upton R.A., Lin E., Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 61:2000;85-94.
6. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 267:1992;2750-2755.
7. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence (see comments). JAMA. 267:1992;2750-2755.
8. Kosten T.R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence (see comments). J. Nerv. Ment. Dis. 181:1993;358-364.
9. Kuhlman J.J. Jr., Levine B., Johnson R.E., Fudala P.J., Cone E.J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 93:1998;549-559.
10. Ling W., Wesson D.R. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 70:2003;S49-S57.
11. Ling W., Wesson D.R., Charuvastra C., Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry. 53:1996;401-407.
12. Mello N.K., Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science. 207:1980;657-659.
13. Mendelson J., Jones R.T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 70:2003;S29-S37.
14. Mendelson J., Upton R.A., Everhart E.T., Jacob P. III, Jones R.T. Bioavailability of sublingual buprenorphine. J. Clin. Pharmacol. 37:1997;31-37.
15. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., Foltz R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 306:2002;31-39.
16. Nath R.P., Upton R.A., Everhart E.T., Cheung P., Shwonek P., Jones R.T., Mendelson J.E. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J. Clin. Pharmacol. 39:1999;619-623.
17. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., Gessa G.L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 60:2000;39-50.
18. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62:2001;97-104.
19. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse (see comments). Arch. Gen. Psychiatry. 54:1997;713-720.
20. Schuh K.J., Johanson C.E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 56:1999;55-60.
21. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacol. Berlin. 154:2001;230-242.
22. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry. 151:1994;1025-1030.
23. Strain E.C., Walsh S.L., Bigelow G.E. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacol. Berlin. 159:2002;161-166.
24. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55:1994;569-580.
25. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274:1995;361-372.